Compare FXNC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | FULC |
|---|---|---|
| Founded | 1907 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.4M | 285.4M |
| IPO Year | 2012 | 2019 |
| Metric | FXNC | FULC |
|---|---|---|
| Price | $31.01 | $3.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 26.5K | ★ 1.6M |
| Earning Date | 05-12-2026 | 04-27-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 96.00 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $7,717,000.00 | N/A |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $2.93 | N/A |
| P/E Ratio | $25.90 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $21.59 | $2.83 |
| 52 Week High | $33.24 | $15.74 |
| Indicator | FXNC | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 52.83 |
| Support Level | $30.71 | $3.44 |
| Resistance Level | $33.02 | $3.96 |
| Average True Range (ATR) | 0.98 | 0.09 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 38.39 | 72.41 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. The company has revenue from Community Banking segment.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.